S6-07 Comparison of 12 weeks neoadjuvant nab

Transcription

S6-07 Comparison of 12 weeks neoadjuvant nab
undefined
S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER:
WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz
Slide 1 / 20
Slide 2 / 20
Page 1
undefined
S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER:
WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz
Slide 3 / 20
Slide 4 / 20
Page 2
undefined
S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER:
WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz
Slide 5 / 20
Slide 6 / 20
Page 3
undefined
S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER:
WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz
Slide 7 / 20
Slide 8 / 20
Page 4
undefined
S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER:
WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz
Slide 9 / 20
Slide 10 / 20
Page 5
undefined
S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER:
WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz
Slide 11 / 20
Slide 12 / 20
Page 6
undefined
S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER:
WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz
Slide 13 / 20
Slide 14 / 20
Page 7
undefined
S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER:
WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz
Slide 15 / 20
Slide 16 / 20
Page 8
undefined
S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER:
WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz
Slide 17 / 20
Slide 18 / 20
Page 9
undefined
S6-07 COMPARISON OF 12 WEEKS NEOADJUVANT NAB-PACLITAXEL COMBINED WITH CARBOPLATINUM VS. GEMCITABINE IN TRIPLE-NEGATIVE BREAST CANCER:
WSG-ADAPT TN RANDOMIZED PHASE II TRIALSpeaker: Oleg Gluz
Slide 19 / 20
Slide 20 / 20
Page 10